IRVINE, Calif. & BALTIMORE–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degenera
A novel ab interno trabeculotomy method reduced IOP and postoperative medication load in the treatment of primary congenital glaucoma and juvenile open-angle glaucoma, according to a study.Gonioscopy-assisted transluminal trabeculotomy (GATT) is a 360° ab interno conjunctival-sparing technique performed through a 23-gauge needle paracentesis track located tangentially in the superonasal or inferonasal quadrant.
Sometimes discoveries in science are not about the development of new medical devices or drugs, but about repurposing existing technologies for new applications. Researchers from University of Sheffield have now used ultrasound to reduce healing times of diabetic wounds by 30%. The study, published in the Journal of Investigative Dermatol (Read more...)
Sometimes discoveries in science are not about the development of new medical devices or drugs, but about repurposing existing technologies for new applications. Researchers from University of Sheffield have now used ultrasound to reduce healing times of diabetic wounds by 30%. The study, published in the Journal of Investigative Dermatol (Read more...)
Technologies such as the Second Sight eye prosthesis can bring back basic vision to some blind people. However, the results are difficult to imagine for those not using such systems. Researchers at the University of Washington wanted to find out what it’s really like to see using a bionic eye, so they performed a […]
The post Si (Read more...)
Regeneron reported $999 million in total revenue in the second quarter, a 50% increase compared with $666 million in the same quarter of 2014, according to a press release. Net sales for Eylea (aflibercept) in the U.S. were reported at $655 million, a …